Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

PIK3CA mutation + ER positive

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

PIK3CA amplification (12)

ER amplification (1)

PIK3CA amplification (12)

ER amplification (1)

›

PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1
PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	GDC-0032 Sensitive: B - Late Trials GDC-0032 Sensitive : B	GDC-0032 Sensitive: B - Late Trials GDC-0032 Sensitive : B
PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	alpelisib Sensitive: C3 – Early Trials alpelisib Sensitive : C3	alpelisib Sensitive: C3 – Early Trials alpelisib Sensitive : C3
PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	palbociclib + GDC-0032 Sensitive: C3 – Early Trials palbociclib + GDC-0032 Sensitive : C3	palbociclib + GDC-0032 Sensitive: C3 – Early Trials palbociclib + GDC-0032 Sensitive : C3
PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	palbociclib Resistant: C3 – Early Trials palbociclib Resistant : C3	palbociclib Resistant: C3 – Early Trials palbociclib Resistant : C3
PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	fulvestrant Sensitive: D – Preclinical fulvestrant Sensitive : D	fulvestrant Sensitive: D – Preclinical fulvestrant Sensitive : D
PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	everolimus Sensitive: D – Preclinical everolimus Sensitive : D	everolimus Sensitive: D – Preclinical everolimus Sensitive : D
PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	palbociclib + alpelisib Sensitive: D – Preclinical palbociclib + alpelisib Sensitive : D	palbociclib + alpelisib Sensitive: D – Preclinical palbociclib + alpelisib Sensitive : D
PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	alpelisib + ribociclib Sensitive: D – Preclinical alpelisib + ribociclib Sensitive : D	alpelisib + ribociclib Sensitive: D – Preclinical alpelisib + ribociclib Sensitive : D
PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	LY4064809 Sensitive: D – Preclinical LY4064809 Sensitive : D	LY4064809 Sensitive: D – Preclinical LY4064809 Sensitive : D